Please login to the form below

Not currently logged in
Email:
Password:

Osmotica Pharmaceuticals appoints new vice president

Samer Kaba joins the firm

Osmotica Pharmaceuticals has appointed Samer Kaba as vice president and head of global clinical development and medical affairs.

Kaba brings experience in developing pharmaceutical products for neurology, analgesia, and autoimmune diseases and has spent 15 years in the pharmaceutical industry in global clinical development programmes from early to late stage development and submission of NDAs and global marketing authorisations.

Praveen Tyle, president and CEO of Osmotica, said: “We are very pleased to have Samer as part of our senior leadership team at such an exciting time as he will be instrumental in further progressing Osmotica's recent achievements in our two lead CNS product candidates – Ontinua ER and Osmolex ER.

“Dr. Kaba's experience in multiple sclerosis will also be instrumental in discussions with FDA for the approval of Ontinua ER, which was accepted for filing by the FDA recently.”

8th October 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....